Eikon Therapeutics (Nasdaq: EIKN) announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE